MBX Biosciences, Inc.’s Post

👏 We are excited to welcome Dr. Steven Heymsfield as a Scientific Advisor to CicadaBio. Steven Heymsfield 🏆 Dr. Heymsfield is one of the world's leading experts in obesity, body composition, and metabolism. His scientific insights will help guide the development of our lead program, including CC-18, as we advance toward the clinic. At CicadaBio, we believe the future of obesity treatment is not simply about helping patients lose more weight—it is about helping them lose weight better by improving quality of weight loss. ✨ This collaboration reflects our commitment to building a strong scientific foundation and developing next-generation obesity therapies that improve not only weight loss, but also body composition and long-term patient outcomes. 🧬 We are honored to have Dr. Heymsfield join us on this journey and look forward to working together to advance next-generation obesity therapies. #Obesity #Biotech #BodyComposition #Musclehealth #MetabolicDisease #Innovation

🔬 What Are Clinical Trial Registries Telling Us About Gut Microbiota and Obesity? A new registry-based systematic review provides a unique snapshot of where microbiome research in obesity is heading, not by looking at completed studies alone, but by examining registered clinical trials worldwide. Key insights 🦠 Clinical trials are increasingly evaluating microbiome-targeted strategies as potential tools for obesity management. 🦠Probiotics remain the primary focus, academic institutions the main sponsors, and China/US the core hubs. The field has entered a post-marketing evaluation phase dominated by Phase IV studies. Read more: https://lnkd.in/e4hjqdha

New revolutionary peptide treatment for acute kidney injury & kidney disease A New Era in Kidney Disease Therapy Kidney disease affects hundreds of millions worldwide, posing a significant global health challenge. Traditional treatments often fall short, offering limited efficacy and sometimes causing unwanted side effects. However, transformative research, including contributions from Prof. Mike Chan and his research team, is revolutionizing the approach to kidney care. The new study, titled “Emerging Peptide Therapies for Kidney Disease: Focus on Nano-Organo and Mitochondria-Targeted Strategies,” delves into life-changing solutions that promise more precise and effective interventions. Nano-Organo Peptides (NOPs) and Mitochondria-Targeted Peptides (MTPs) are emerging precision therapies for Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD), addressing the limitations of conventional treatments like poor renal selectivity and systemic toxicity.  Published in the American Journal of Biomedical Science & Research in 2025 by Mike K.S. Chan, Michelle B.F. Wong, Krista Casazza, and Jonathan R.T. Lakey https://lnkd.in/eDaV2szD

Scientists may be closer than ever to changing the future of osteoarthritis (OA)—the world's most common form of arthritis. A landmark international study has revealed that OA is not a collection of different diseases, as previously believed, but a single disease driven by common biological pathways. This breakthrough provides researchers with a clearer target for developing disease-modifying treatments that could slow, stop, or even reverse cartilage damage, rather than simply managing pain. The findings, published in Nature Communications, analyzed thousands of proteins from knee joint samples, helping scientists identify the molecular mechanisms responsible for cartilage breakdown and inflammation. This discovery is expected to accelerate precision therapies, improve early diagnosis, and increase the success rate of future clinical trials. While a definitive cure is not yet available, experts believe this research marks one of the most significant steps toward preventing osteoarthritis progression and restoring joint health. Submit your related work via email here: cancer@genesispub.org #Osteoarthritis #MedicalResearch #HealthcareInnovation #Biotechnology #RegenerativeMedicine #PrecisionMedicine #ArthritisResearch #ClinicalResearch #FutureOfHealthcare #LifeSciences #DigitalHealth #HealthTech #Innovation #Science

BREAKING NEWS Scientists have pinpointed a revolutionary biological marker that directly tracks body fat fluctuations. This discovery offers unprecedented insight into the intricate dance between weight gain weight loss and metabolic health unlocking new avenues for therapeutic development. This finding promises to reshape our understanding of obesity and related conditions 💡. The research published in Metabolism details how this dynamic biomarker mirrors changes in adipose tissue volume. Its reliable correlation with fat mass represents a significant leap forward enabling more precise monitoring of metabolic shifts. This could pave the way for personalized interventions and early detection of metabolic disturbances 🔥. This groundbreaking identification marks a pivotal moment in metabolic research potentially revolutionizing the fight against obesity and its associated health challenges. The ability to dynamically measure fat changes opens doors for novel treatment strategies and improved patient outcomes worldwide 🌎. #MetabolicHealth #ObesityResearch #BiomarkerDiscovery #MedicalBreakthrough #WeightManagement

🧬 Could achieving a complete molecular response improve outcomes after allogeneic HSCT in Philadelphia chromosome–positive ALL? In this expert discussion, Dr. Talha Badar of Mayo Clinic explores the factors associated with complete molecular response and how they may influence transplant outcomes in patients with Ph+ ALL. Topics include: • Predictors of complete molecular response • Risk stratification in Ph+ ALL • Allogeneic HSCT outcomes • Implications for treatment planning 🎥 Watch the full video on #Vumedi: https://lnkd.in/eUa4zT_4 #AcuteLymphoblasticLeukemia #StemCellTransplant

🤔 Could GLP-1 medications influence alcohol-related outcomes? Today, a new study was published in BMJ Open using Truveta Data analyzed more than 40,000 adults with alcohol use disorder and either type 2 diabetes or obesity. We sat down with one of the study's co-authors, Hemalkumar Mehta, PhD to learn what they uncovered. Researchers found that patients who initiated newer GLP-1 receptor agonists, including semaglutide and tirzepatide, had lower rates of alcohol-related emergency department visits and hospitalizations than those receiving alternative treatments. Using target trial emulation, the study adds rigorous real-world evidence to an emerging area of research. 🔗 Read the full paper: https://tr.vet/4ffZXgx

One of the defining features of obesity is its biological complexity. As our understanding of the disease continues to evolve, it has become increasingly clear that no single mechanism is likely to address the needs of every patient. I believe the future of obesity treatment will increasingly be shaped by therapies that engage complementary biological pathways to address that complexity. Today, Boehringer Ingelheim announced the initiation of a Phase 2 clinical trial of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist discovered through the collaboration between Gubra and Boehringer Ingelheim. BI 3034701 reflects a differentiated approach to obesity treatment, designed to engage complementary biological pathways involved in appetite regulation, energy balance, and metabolic health. To me, BI 3034701 reflects the kind of innovation the obesity field needs. Expanding the biological pathways we can target will be essential to building a broader toolbox for future obesity treatment. Strong scientific partnerships are equally important in translating those discoveries into clinical development. Congratulations to the teams at Boehringer Ingelheim and Gubra who have contributed to bringing BI 3034701 to this important milestone. I look forward to following the program's continued progress and the scientific insights that emerge from the Phase 2 study. #Obesity #DrugDiscovery #gubra #ClinicalDevelopment #MetabolicDisease #Biotech

https://lnkd.in/eWAJxugW For decades, osteoarthritis has been treated primarily as a local joint problem. New evidence suggests we may have been looking at only part of the picture. A recent review proposes that OA is influenced by a dynamic gut-brain-liver-kidney network, where microbial metabolites, neuroendocrine signaling, metabolic health, and systemic inflammation all contribute to disease progression and pain. It also helps explain why between 12% of hip replacements and 20% of knee replacements are accompanied by ongoing chronic pain. Researchers argue that understanding these connections could unlock more targeted, mechanism-based therapies. The future of OA management may depend not only on protecting cartilage, but also on improving metabolic, neurological, and gut health. A reminder that in medicine, no organ operates in isolation. #Osteoarthritis #PrecisionMedicine #SystemsBiology #DigitalHealth #MedicalResearch

#PRESS: Today marks an important milestone for obesity science and for the people who may benefit from it. The European Commission has approved our oral GLP-1 treatment for weight management, the first of its kind in the European Union, as well as higher-dose 7.2 mg injectable semaglutide in a single-dose device. As a scientist, what makes this moment especially meaningful is what it represents. Developing an oral formulation of semaglutide has required years of research, innovation, and clinical development. It reflects collaboration across many scientific disciplines and the commitment of colleagues across Novo Nordisk to advancing obesity care. These approvals also reinforce an important principle: people living with obesity have different needs and preferences. Expanding treatment options gives healthcare professionals and people living with obesity more choice when deciding on the right treatment. I am incredibly proud of the teams that have made these milestones possible. Seeing years of research translated into new treatment options for people living with obesity is a reminder of why we do what we do - and it motivates us to keep pushing the boundaries of science.